BIOCRYST PHARMACEUTICALS, INC. Repayments of Lines of Credit
BIOCRYST PHARMACEUTICALS, INC. (BCRX) reported Repayments of Lines of Credit of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-27.
Discontinued › Cash Flow › Financing Activities
us-gaap:RepaymentsOfLinesOfCredit · last filed 2023-02-27
- BIOCRYST PHARMACEUTICALS, INC. repayments of lines of credit for the quarter ending 2021-12-31 was $0.00, a 100.00% decline year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. repayments of lines of credit for the quarter ending 2020-12-31 was $47.42M.
- BIOCRYST PHARMACEUTICALS, INC. repayments of lines of credit for the quarter ending 2018-12-31 was $0.00.
- BIOCRYST PHARMACEUTICALS, INC. repayments of lines of credit for the quarter ending 2018-09-30 was $575.00K.
- BIOCRYST PHARMACEUTICALS, INC. repayments of lines of credit for fiscal 2022 was $0.00.
- BIOCRYST PHARMACEUTICALS, INC. repayments of lines of credit for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- BIOCRYST PHARMACEUTICALS, INC. repayments of lines of credit for fiscal 2020 was $52.42M.
- BIOCRYST PHARMACEUTICALS, INC. repayments of lines of credit for fiscal 2018 was $4.03M.
| Period end | Repayments of Lines of Credit 3 month | Repayments of Lines of Credit 6 month | Repayments of Lines of Credit 9 month | Repayments of Lines of Credit 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 10-K · filed 2023-02-27 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $0.00 10-K · filed 2023-02-27 | ||
| 2021-09-30 | $0.00 10-Q · filed 2021-11-04 | |||
| 2020-12-31 | $47.42M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $52.42M 10-K · filed 2023-02-27 | ||
| 2020-09-30 | $5.00M 10-Q · filed 2021-11-04 | |||
| 2019-09-30 | $0.00 10-Q · filed 2020-11-06 | |||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $575.00K derived: sum of 2 quarters · filed 2021-03-01 | $2.30M derived: sum of 3 quarters · filed 2021-03-01 | $4.03M 10-K · filed 2021-03-01 |
| 2018-09-30 | $575.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | $2.30M derived: sum of 2 quarters · filed 2019-11-08 | $4.03M 10-Q · filed 2019-11-08 | |
| 2018-06-30 | $1.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $3.45M 10-Q · filed 2019-08-08 | ||
| 2018-03-31 | $1.73M 10-Q · filed 2019-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |